Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The LeVeen shunt.

H H LeVeen

    Annual Review of Medicine
    |January 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    The peritoneovenous shunt effectively treats ascites by returning fluid to the plasma, averting renal failure. Careful patient monitoring is crucial to prevent infection and ensure shunt success.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Chemical, physiological, and pathological observations on the role of pepsin and hydrochloric acid in the production of experimental ulcers.

    Gastroenterology·2010
    Same author

    Combination of Evans blue with plasma protein; its significance in capillary permeability studies, blood dye disappearance curves, and its use as a protein tag.

    The American journal of physiology·2010
    Same author

    Some physiologic and biochemical alterations incident to surgical intervention; report of a case.

    Archives of surgery (Chicago, Ill. : 1920)·2010
    Same author

    Total peptic activity of gastric juice; a method of determination.

    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)·2010
    Same author

    Active pepsin fraction, resting peptic activity, and percentage of pepsin inhibition in gastric juice.

    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)·2010
    Same author

    Awakenings to the pathogenicity of urease and the requirement for continuous long term therapy.

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·1994
    Same journal

    Dupilumab Emerges as an Effective Antibody Therapy for Eosinophilic Esophagitis.

    Annual review of medicine·2026
    Same journal

    CAR T Cell Toxicities and Emerging Treatment Strategies.

    Annual review of medicine·2026
    Same journal

    Transthyretin Amyloid Cardiomyopathy: A Rapidly Evolving Landscape.

    Annual review of medicine·2026
    Same journal

    Accessibility of Somatic Genetic Testing for Cancer Treatment Decisions.

    Annual review of medicine·2026
    Same journal

    Diffuse Parenchymal Lung Disease: Updates in Pathophysiology and Management.

    Annual review of medicine·2026
    Same journal

    Revascularization for Ischemic Cardiomyopathy: Disproving the 45-Year-Old Concept of Hibernating Myocardium.

    Annual review of medicine·2026
    See all related articles

    Area of Science:

    • Gastroenterology
    • Nephrology
    • Surgical Innovation

    Background:

    • Ascites results from an imbalance between plasma-to-peritoneal fluid formation and reabsorption.
    • Current management of ascites often fails to address the underlying fluid dynamics.
    • Physiologic therapy aims to restore fluid balance by returning peritoneal fluid to the plasma volume.

    Purpose of the Study:

    • To evaluate the efficacy and safety of the peritoneovenous shunt for managing ascites.
    • To determine the impact of the peritoneovenous shunt on patient mortality and morbidity.
    • To assess the potential for liberalizing indications for peritoneovenous shunt placement.

    Main Methods:

    • The study reviews the application of the peritoneovenous shunt in ascites management.

    Related Experiment Videos

  • Emphasis is placed on precautionary measures to avoid complications.
  • Analysis includes mortality rates, complication avoidance, and shunt failure management.

    • Main Results:

    • Peritoneovenous shunt placement achieves a mortality rate under 1% in uncomplicated cirrhosis.
    • Avoidable complications include postoperative coagulopathy and infection.
    • Shunt failure is manageable, and early renal failure, a common cause of death, is averted.
    • The shunt does not prevent esophageal varices, which require separate management.

    Conclusions:

    • The peritoneovenous shunt is an effective treatment for ascites with minimal morbidity and mortality.
    • Careful postoperative monitoring is essential to prevent late sepsis in cirrhotic patients.
    • Indications for peritoneovenous shunt placement should be expanded due to its favorable outcomes.